financetom
Business
financetom
/
Business
/
Hess Midstream Q4 Net Income, Revenue Rise; Issues 2025 Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Hess Midstream Q4 Net Income, Revenue Rise; Issues 2025 Guidance
Jan 29, 2025 5:58 AM

08:35 AM EST, 01/29/2025 (MT Newswires) -- Hess Midstream LP ( HESM ) reported Q4 net income Wednesday of $0.68 per diluted share, up from $0.55 a year earlier.

Analysts polled by FactSet expected $0.68.

Total revenue for the quarter ended Dec. 31 was $395.9 million, up from $356.5 million a year earlier.

Four analysts surveyed by FactSet expected $390.9 million.

Separately, the company said it expects 2025 net income of $715 million to $765 million. Analysts polled by FactSet expect $315.1 million.

The company expects 2025 capital expenditures of about $300 million.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
USTR says decision on Section 301 tariffs on Chinese imports to be announced in coming days
USTR says decision on Section 301 tariffs on Chinese imports to be announced in coming days
Aug 30, 2024
WASHINGTON (Reuters) - The U.S. Trade Representative's office said on Friday it was continuing to develop final determination on Section 301 tariffs on Chinese imports and will make a decision public in the coming days. USTR continues to develop the final determination regarding proposed modifications of the actions in the Section 301 investigation of the People's Republic of China's Acts,...
Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart Muscles
Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart Muscles
Aug 30, 2024
Friday, Alnylam Pharmaceuticals Inc. ( ALNY ) stock is trading lower after the company shared detailed results from the HELIOS-B Phase 3 study of vutrisiran for ATTR amyloidosis with cardiomyopathy (ATTR-CM). Topline data was revealed in June. The data were presented at the European Society of Cardiology Congress 2024. Also Read: Roche/Alnylam Blood Pressure Drug Aces In Mid-Stage Trial, Analyst...
Solar Module Company JinkoSolar's Q2 Earnings: 22% Revenue Drop, Margins Hit By Lower Average Selling Price
Solar Module Company JinkoSolar's Q2 Earnings: 22% Revenue Drop, Margins Hit By Lower Average Selling Price
Aug 30, 2024
JinkoSolar Holding Co ( JKS )  stock tanked Friday premarket after the company reported second-quarter results. The solar module manufacturer’s revenue decreased 21.6% year-over-year to $3.31 billion, missing the analyst consensus estimate of $3.91 billion. Adjusted earnings per ADS of $0.99 beat the analyst consensus estimate of $0.17. Quarterly shipments increased 36.0% Y/Y to 25,318 MW (23,822 MW for solar modules...
Leveraged Nvidia ETF issuers saw trading surge in bearish products ahead of earnings
Leveraged Nvidia ETF issuers saw trading surge in bearish products ahead of earnings
Aug 30, 2024
Aug 29 (Reuters) - Interest in leveraged exchange-traded funds that allow investors to profit when shares of Nvidia ( NVDA ) fall grew steadily ahead of the chipmaker's quarterly results, according to data from some of the companies that issued the products. Nvidia ( NVDA ), which in June eclipsed Microsoft ( MSFT ) as the world's most valuable company,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved